The stock price of Ginkgo Bioworks Holdings, Inc. experienced a significant rise of 10.60% fueled by several key factors. Firstly, the company's shares outperformed other ETF components, particularly within the ARK Genomic Revolution ETF, showcasing notable strength in trading activities. Despite recent stock value decreases, Ginkgo Bioworks demonstrated robust revenue growth over the past years, hinting at future potential. The company's revenue surged significantly in the last quarter, surpassing analyst estimates, reflecting strong market performance and investor confidence. Additionally, Ginkgo Bioworks' involvement in rapid vaccine development programs, as evidenced by its contract with HDT Bio, highlights the company's innovative approach and strategic partnerships in the biotech sector. These collective factors contributed to the notable increase in Ginkgo Bioworks' stock price and market capitalization.